Conventional antidepressants require 2-8 weeks for a full clinical response. In contrast, two rapidly acting antidepressant interventions, low-dose ketamine and sleep deprivation (SD) therapy, act within hours to robustly decrease depressive symptoms in a subgroup of major depressive disorder (MDD) patients. Evidence that MDD may be a circadian-related illness is based, in part, on a large set of clinical data showing that diurnal rhythmicity (sleep, temperature, mood and hormone secretion) is altered during depressive episodes. In a microarray study, we observed widespread changes in cyclic gene expression in six regions of postmortem brain tissue of depressed patients matched with controls for time-of-death (TOD). We screened 12 000 transcripts and observed that the core clock genes, essential for controlling virtually all rhythms in the body, showed robust 24-h sinusoidal expression patterns in six brain regions in control subjects. In MDD patients matched for TOD with controls, the expression patterns of the clock genes in brain were significantly dysregulated. Some of the most robust changes were seen in anterior cingulate (ACC). These findings suggest that in addition to structural abnormalities, lesion studies, and the large body of functional brain imaging studies reporting increased activation in the ACC of depressed patients who respond to a wide range of therapies, there may be a circadian dysregulation in clock gene expression in a subgroup of MDDs. Here, we review human, animal and neuronal cell culture data suggesting that both low-dose ketamine and SD can modulate circadian rhythms. We hypothesize that the rapid antidepressant actions of ketamine and SD may act, in part, to reset abnormal clock genes in MDD to restore and stabilize circadian rhythmicity. Conversely, clinical relapse may reflect a desynchronization of the clock, indicative of a reactivation of abnormal clock gene function. Future work could involve identifying specific small molecules capable of resetting and stabilizing clock genes to evaluate if they can rapidly relieve symptoms and sustain improvement.
INTRODUCTION
Circadian function is frequently disrupted during depressive episodes. When rhythms are dysregulated, the risk for disease 1 including depression 2 increases. Clinical findings suggest a relationship between the degree of desynchronization in circadian rhythms and the severity of depressive symptoms. 3 As symptoms improve, normal rhythms are frequently restored. 4 Low-dose ketamine and sleep deprivation therapy (SDT) can act within hours to robustly decrease symptoms of depression, in striking contrast to the 2-8 weeks required by conventional antidepressants for a full clinical response. 5, 6 It is proposed that lowdose ketamine 7, 8 and SDT 9, 10 act, in part, on circadian machinery to restore normal behavioral and physiological circadian rhythms. 11 
ABNORMAL CIRCADIAN RHYTHMS IN MAJOR DEPRESSIVE DISORDER (MDD)
A dysregulation in diurnal rhythmicity affecting sleep, mood, temperature and hormone secretion is reported in a subgroup of MDD patients.
Sleep
Sleep is regulated by homeostasis (sleep pressure) and circadian (diurnal timing of sleep) processes. Circadian regulation of sleep is reported to be independent of prior wakefulness, differentiating it from homeostasis, although data in humans and rodents suggest an interaction. [12] [13] [14] [15] Insomnia, a major symptom of depression affecting about 80% of patients, is characterized by difficulty in falling asleep, staying asleep, early morning awakening and/or shortened rapid eye movement latency-symptoms compatible with a shift in circadian phase. 16 Chronic insomnia is associated with an increased risk for recurrent depressive episodes [16] [17] [18] [19] [20] as well as suicidality. 21 Normalization of sleep patterns may be an early predictor of antidepressant response. [22] [23] [24] Mood Diurnal variations in mood are normal in healthy controls. However, mood swings in depression can vary to extremes. For example, some patients awaken in early morning with severe psychotic symptoms and by evening, improve to an almost euthymic state. 25, 26 Marked patterns in mood swings can persist throughout the depressive episode.
Temperature Thermoregulation has a critical role in biological function and as reported in human fibroblasts, as little as 1°C change can significantly alter circadian gene expression. 27 In healthy controls, 1 core body temperature rises in early morning hours and decreases at night. Depressed patients often have 'flattened' diurnal rhythms as nocturnal temperatures remain high. 28, 29 Remission is usually associated with a decrease in nocturnal temperature and a restoration of normal rhythms. 28, 30 Hormone secretion Corticosteroids. Depression is often associated with hypothalamicpituitary-adrenal axis overactivation. Cortisol and its relevant peptides measured in saliva, cerebrospinal fluid and urine (24-h urinary cortisol and its major breakdown product, 17-hydroxycortisolsteroids) are often elevated. High cortisol levels may be sustained throughout the day-a finding most pronounced in psychotically depressed suicidal individuals. 31 Morning cortisol peaks may also be phase-advanced by 2-3 h. [32] [33] [34] [35] In remission, evening cortisol levels may decrease to normal levels 36 although not consistently. 37 Melatonin. Melatonin, the primary hormone of the pineal gland, has been used as a marker of circadian phase. Secreted at night, the timing of melatonin release under dim light conditions (dim light melatonin onset) has been phase-delayed in depression. [38] [39] [40] [41] It should be noted that abnormalities in circadian function, although frequently reported in MDD can also be associated with bipolar disorder, psychosis and schizophrenia. 31, [42] [43] [44] In addition, some depressed patients may not have any symptoms of circadian dysregulation, while others have striking changes in daily rhythms. Chronotherapeutic antidepressant strategies (SDT, bright light therapy and sleep phase advance) are effective in 40-60% of severely depressed patients. 4 The subset of patients who do not respond to chronotherapeutic treatment strategies may not have depression-related circadian abnormalities.
CIRCADIAN CLOCK GENES
Modulation of circadian rhythms Circadian rhythms are generated, in part, by clock genes that are under the control of a small pair of nuclei in the anterior hypothalamus, the suprachiasmatic nucleus (SCN). The SCN receives extensive input from many brain regions and serves as a primary modulator of virtually all cellular clocks in the body. The SCN maintains synchrony by resetting circadian rhythms via photic and non-photic signaling. 45, 46 In addition, relevant to antidepressant medications, rhythmic release of 5-hydroxytryptamine is modulated by intrinsic feedback to the raphe, 47 which can synchronize circadian rhythms in SCN and peripheral tissue. 48, 49 Circadian clock gene machinery At the molecular level, a core set of clock genes (bmal1, clock, period (per1,2,3), cryptochrome (cry1,cry2) and their protein products have a central role in generating virtually all rhythms throughout the body. In the nucleus, BMAL1/CLOCK (or NPAS2-a paralog of CLOCK) form a heterodimer that binds to E-Boxcontaining promoters on per and cry genes. Per and Cry mRNAs move into the cytoplasm and are translated into their respective proteins to form heterodimers (PER/CRY). The PER/CRY heterodimers form a complex with casein kinase1ε enabling their translocation back into the nucleus to inhibit their own transcription by interacting with BMAL1/CLOCK. 50 Multiple interlocking transcriptional-translational loops contain both positive and negative transcription factors that adjust rhythms to an approximate 24-h cycle. A subset of these loops includes orphan nuclear receptors that confer stability to the core circadian interactions. For example, Bmal1 rhythmicity is modulated by Rorα that activate Bmal1 transcription, while Rev-rbα represses Bmal1 transcription via common retinoid-related orphan receptor elements on the Bmal1 promoter. Conversely, BMAL1/CLOCK activates Rev-erbα, thus forming a link between the positive and negative loops. Additional clock genes, Dec1 and Dec2, repress transcription of BMAL1-enhanced promoter activity by binding directly to Enhancer boxes (E-boxes) (per and cry interact with the BMAL1/ CLOCK heterodimer but cannot bind directly to E-boxes as they lack DNA binding domains). 51, 52 The high degree of complexity involved in the molecular architecture of circadian regulation has been reviewed elsewhere. 53 
HUMAN STUDIES OF CIRCADIAN CLOCK GENES
Pineal gland Wu et al. 54 were the first to demonstrate robust rhythmic expression of clock genes (Bmal1, Cry1 and Per1) in pineal gland in control subjects and its dysregulation in Alzheimer disease patients. Samples collected around the clock according to time-of-death (TOD) (that is, dawn, day, dusk and night) showed time-of-day-dependent effects. Peaks in gene expression occurred at dawn (Bmal1), dawn and dusk (Per1) and evening (Cry1). Ackermann et al. 55 also analyzed pineal tissue in controls and although they did not replicate Wu et al.'s 54 results, they discovered time-dependent nucleocytoplasmic shuttling of clock proteins (PER1, CRY1, CLOCK and BMAL1) (Clock proteins 'shuttle' between the nucleus and cytoplasm as part of the regulatory feedback loop to generate rhythms). Peak times for translocation of the circadian proteins occurred at dawn (PER1 and CLOCK), day (CRY1) and night (Bmal1).
Pituitary
Although clock gene proteins are detectable in pituitary, Per1 was the only circadian gene to show robust diurnal rhythms (lowest levels at dusk). In contrast to other brain regions, clock genes and their proteins in pituitary are hypothesized to primarily modulate time-dependent hormone synthesis. 56 First report of an abnormal clock gene in suicides vs non-suicides in postmortem brain tissue Sequiera et al. 57 analyzed the dorsolateral prefrontal cortex in suicide and non-suicide depressed patients and reported a significant downregulation in per1 in suicide victims. Although per1 was analyzed at only one time-point, to our knowledge this was the first study in brain to report that suicide may be associated with a dysregulation in a core clock gene critical to circadian function.
First evidence of a significant disruption in circadian clock genes in six brain regions in MDD patients contrasted with controls We conducted a microarray study in brain tissue comparing circadian gene expression in control subjects and MDD patients. Six brain regions relevant to the psychopathology of MDD were selected for investigation. Microarray analyses including 12 000 transcripts identified genes with the most robust sinusoidal 24-h rhythms 58 in anterior cingulate (ACC), dorsolateral prefrontal cortex, hippocampus, amygdala, nucleus accumbens and cerebellum as part of a multicenter Pritzker Neuropsychiatric Disorders Research Consortium study. High-quality postmortem brain tissue was collected-all cases had sudden death, pH values 46.5 (average pH = 6.87), and completion of a psychological autopsy (141 item questionnaire) with next-of-kin. Control cases were confirmed by family interviews with next-of-kin to rule out psychiatric illness in controls as well as in first-degree relatives. Diagnoses in MDD patients were confirmed by medical records, family interviews and reviewed by two psychiatrists. To discover the cyclic genes, we fit the expression values for each gene by a sinusoidal function of time using the method of least squares and fixing the period at 24 h. The statistical significance of the findings was evaluated by permutation, randomly assigning TOD data across subjects 1000 times. Peak levels of sinusoidal rhythms were determined (as described in Li et al. 58 ).
Control subjects. Our data provide evidence that clock gene sinusoidal rhythms vary in synchrony over 24 h across six regions in control human brain. Results showed that Bmal1 ranked at the top of 12 000 transcripts in terms of consistency for time of peak expression across six brain regions. Period genes (per1, per2 and per3), Rev-erbα, Dbp, and Dec 2 ranked in the top 11 for having the most robust rhythms. Remarkably, the temporal expression pattern of per genes in our human data across all six brain regions was in agreement with that in rodent SCN 59 whereby per1 levels peaked in early morning, per3 peaked 5 h later and per2 levels peaked 8 h later.
MDD patients. Results showed a significant and marked loss in rhythmicity in the top-ranked cyclic genes in the patients compared with controls and provide the first direct evidence of a disruption in clock gene expression in MDD. These findings were independent of the cause of death and medication (evaluated by toxicology screens).
Evidence that the anterior cingulate (ACC) may be a site for clock gene dysfunction Converging data from neuroimaging, neuropathological and lesion studies implicate the ACC as important in the regulation of mood. The ACC is a major component of a large extended neural network including the hippocampus, striatum and amygdala. As reviewed by Drevets et al., 60 preclinical and clinical findings present convincing evidence to suggest that impairment in the ACC could contribute to symptoms of depression. Moreover, deep brain stimulation in subgenual ACC ameliorates symptoms of depression in treatmentresistant MDD patients. 61 Structural abnormalities (for example, decreased gray matter volume) and reductions in cognitive performance are also associated with depression. 62 A large body of functional brain imaging studies (for example, fMRI, PET, EEG, qEEG, SPECT and MEG) report increased activation in the ACC of depressed patients who respond to a wide range of therapies including conventional antidepressants [63] [64] [65] [66] [67] [68] [69] and low-dose intravenous ketamine. 63, 70 Similarly, clinical response to nonpharmacological interventions such as SDT, 71 ECT, 72,73 rTMS, 74, 75 deep brain stimulation 76 and cognitive behavioral therapy 77 are also associated with elevated pretreatment ACC activation.
Evidence that clock gene expression is altered in the ACC comes from our microarray analyses of postmortem brain tissue from 34 MDD patients and 34 controls matched for TOD (Supplementary Material, Li et al. 58 ). We found that 11 of the 12 top-ranked circadian genes in the ACC including core clock genes (Bmal1, Per1, Per2, Per3 and Dbp) had significant sinusoidal rhythmicity, whereas only 1 of 12 genes reached statistical significance in the MDDs (Table 1) . We interpret these findings to suggest that in addition to other abnormalities in ACC in depression, a subgroup of MDDs may also have dysregulated clock gene expression. Our findings offer the potential for applying multilevel analyses in genomics to assess the critical role of circadian rhythm disruption in mood disorders. 78 Thus, converging evidence from neuropathological investigations, brain imaging data and clock gene abnormalities support the ACC as a candidate region for future investigations.
Animal models of depression are associated with alterations in circadian genes Although our review is focused primarily on human clinical data, we briefly review relevant animal findings.
Three animal models of depression measuring clock gene expression were studied in rodents including chronic unpredictable stress (CUS), chronic restraint and social defeat. In rats, CUS administered for 28 days produced irreversible depressive-like behaviors. CUS-related changes in SCN included a transient decrease in Per2 amplitude, which normalized following termination of the stressors. Pretreatment with desipramine, blocked both depressive-like behavior and decreases in Per2. 79 In hippocampus (CA1, CA3), CUS-related phase-shifts in Clock gene expression persisted at least 2 weeks beyond the termination of the stressors along with the depressive-like behavior. A follow-up investigation showed that knockdown of Clock in normal rats produced depressive-like behavior suggesting that dysregulated Clock gene expression in HC could contribute to CUS-related depressive behaviors. 80 Other findings in rodents subjected to chronic restraint indicated that a downregulation in Per2 and a concomitant upregulation in glycogen synthase kinase 3 (GSK-3β) in SCN, HC and prefrontal cortex. Nighttime administration of lithium, normalized Per2 and reduced GSK-3β levels to control values. 81 Landgraf et al. 82 provide a critical review of animal studies relevant to the role of clock genes in mood disorders. They discuss limitations in current research including noncircadian effects of clock genes, the difficulty in identifying behavioral tests, which encompass the complex phenotypes of mood disorders. They also suggest that altering light-dark cycles in rodent mutant models could help identify circadian effects of modulation of mood and point out that current animal studies do not provide sufficient data to explain depressive-vs manic-like behavior. Importantly, it is suggested that studies of single-cell rhythms, amplitude and phase in brain areas related to mood could provide critical data describing the relationship of circadian rhythms and mood regulation.
Of interest is whether amphetamines, which do not have significant antidepressant effects, alter circadian clock gene expression. In striatum of rodents, chronic amphetamine shifted per1 and per2 from nocturnal to diurnal expression patterns whereas bmal1 expression patterns switched from diurnal to nocturnal. 83 In other work, amphetamine restored abnormal locomotor rhythms in Clock mutant mice. 84 Clinically, the high rate of comorbidity with addiction (that is, methamphetamine) makes it difficult to extrapolate these findings to MDD patients.
RAPID-ACTING ANTIDEPRESSANT TREATMENTS
Sleep deprivation therapy (SDT) Keeping patients awake for approximately 36 h markedly relieves depressive symptoms in 40-60% of patients. 9 Although relapse rates are high following recovery sleep, chronotherapeutic interventions such as morning bright light therapy (10 000 lux) and sleep phase advance (setting sleep time earlier and advancing bedtimes over subsequent nights) are effective in sustaining improvement for weeks to months. [85] [86] [87] In Europe, SDT is often recommended as a first-line treatment for depression. 10, 87, 88 Actions on clock gene machinery in animals Studies of clock gene expression in mice suggest that sleep deprivation (SD) can produce rapid (within hours) alterations. Prolonged wakefulness elevated Per1 and Per2 levels in cerebral cortex, basal forebrain and hypothalamus, which returned to control values following recovery sleep. 89, 90 A possible mechanism of action could involve the alterations of DNA binding of the core-clock transcription factors to cis-regulatory sequences of target clock genes as evidenced by inhibition DNA binding of (CLOCK/BMAL1 or NPAS2). 91 Further, SD had region-specific effects on immediateearly gene expression such that in SCN, clock gene expression was time-of-day dependent, whereas in neocortex, immediate-early gene expression was a function of time awake and/or cell type. 92 Overall, SD suppresses approximately 80% of circadian genes in brain suggesting that many of the diurnal variations in circadian gene expression are likely sleep-wake dependent. 93 A limitation to the interpretation of these findings relevant to MDD is that to our knowledge none of these studies were conducted in animal models of depression.
Possible role of GSK-3β, α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA), glutamate and mTOR on circadian rhythms Glycogen synthase kinase 3β. It is reported that SDT response rates are higher in depressed patients who carry a gene promoter polymorphism (rs334558) for decreasing GSK-3β activation. 94, 95 GSK-3β, a key component of the Wnt pathway, is upstream of the mammalian target of rapamycin (mTOR) pathway 94 and has a critical role in stabilizing and lengthening the period of biological rhythms. 96, 97 Multiple therapeutic interventions effective in treating depression including mood stabilizers such as lithium, serotonergic antidepressants, as well as low-dose ketamine increase GSK-3β phosphorylation suggesting that GSK-3β inhibition could be a candidate target for antidepressant interventions. In support of this hypothesis is a study showing that GSK-3β levels are elevated in prefrontal cortex of MDDs. 98 AMPA. SD was found to significantly elevate AMPA levels in cerebral cortex. 99, 100 In mice, microinjections of AMPA into the SCN rapidly and robustly induced Per1 expression and phase delays in behavioral rhythms when administered during early subjective night. AMPA receptors are thought to be critical for entrainment by relaying photic information to the SCN. 101 Glutamate. SD is reported in one study to increase N-methyl-Daspartate receptor 2A (NMDAR) receptors in mouse cerebral cortex, 102 while another suggested that SD inhibits NMDAR receptor trafficking in HC. 103 It is hypothesized that both AMPA and N-methyl-D-aspartate (NMDA) signaling reciprocally regulate glutamatergic signaling and the magnitude of phase-shifts. 101 Mammalian target of rapamycin. SD was shown to decrease total and phosphorylated mTOR in HC, an effect that was reversible with recovery sleep. 104 mTOR exhibits robust rhythmicity in the SCN and is activated in a phase-dependent manner by light. Inhibition of mTOR decreases Per1 and Per2 expression and modulates behavioral shifts in animals in the SCN. 105 Peripheral measures of clock genes in humans Disruptions in sleep including restricting sleep, altering sleep times and SD can profoundly affect the temporal organization of the human blood transcriptome including clock gene expression and chromatin modification in healthy volunteers. 106, 107 A study conducted in 12 young healthy males assessing clock gene expression in leukocytes reported that after one night of SD, Bmal1 showed a 70% decrease in amplitude and suppression of rhythmicity whereby expression patterns of per 1,2,3 or Rev-erbα expression were not altered. 108 Analyses of peripheral blood mononuclear cells in six healthy volunteers collected at 4-h intervals over 3 consecutive days (baseline, night of SD and recovery sleep) showed mixed results. Following SD, three subjects showed a loss in Per2 rhythmicity, whereas two subjects were phase shifted. In contrast to findings in leukocytes, SD did not affect Bmal1. 109 To our knowledge, only one study focused on the effect of SD on clock genes in depressed patients. Lavebratt et al.
110 measured Cry2 mRNA in peripheral blood mononuclear cells comparing bipolar depressed patients and healthy male controls. Cry2 mRNA levels were assessed approximately every 6 h in the controls over a period of 48 h. Results showed a marked diurnal rhythm in Cry2 expression. Sleep loss increased Cry2 mRNA levels by twofold in controls. A finding in depressed patients was that these individuals had significantly lower levels of Cry2 at baseline. SD had no significant effect on Cry2 levels in the depressed patients. Although this study was conducted in bipolar patients, the findings could have implications for MDD.
Low-dose ketamine treatment for mood disorders Intravenous low-dose ketamine as reported in 17 studies (see review Bunney and Bunney 4 ) has rapid-acting antidepressant actions with robust efficacy in treatment-resistant depression. The time to response is usually within 2-4 h following ketamine administration. Approximately, one-third of responders have sustained improvement lasting 1-2 weeks. 111 Low-dose ketamine is also a rapidly effective treatment for decreasing suicidality. [112] [113] [114] [115] [116] Intramuscular ketamine, 117 oral ketamine 118 and intranasal routes of administration 119 have been used successfully in open trials to decrease depressive symptoms.
Possible mechanisms of action involving clock genes and circadian-regulated GSK-3β, AMPA, glutamate and mTOR NMDA antagonist. Ketamine is a non-competitive high-affinity NMDAR glutamate receptor antagonist with a half-life of 2-3 h when administered intravenously. 120 It binds within the phencyclidine channel and increases presynaptic release of glutamate, which in turn activates post-synaptic glutamatergic sites including AMPA receptors. At low doses, ketamine increases synaptic plasticity most likely through its inhibitory actions on NMDAmediated glutamatergic receptors. 121, 122 Ketamine's effects on clock gene machinery in neuronal cell culture (preliminary data) We addressed the question as to whether ketamine acts at the clock gene level to modify gene expression using neuronal cell culture (NG108-15). 123 Our results showed that ketamine blunted the amplitude of the transcription of bmal1, per2 and cry1 in a dose-dependent manner. We next mutated the E-Box and found that ketamine's effects on per2 and cry1 transcription were blocked, therefore suggesting that E-box elements may be essential to ketamine's actions. Using chromatin immunoprecipitation (ChIP) analyses, we showed that ketamine altered the recruitment of the BMAL1/CLOCK complex on circadian promoters in a time-dependent manner. We tested various protein kinase inhibitors on the repressive effect of ketamine on the recruitment of BMAL1/CLOCK to its target promoter, and found that only the protein kinase that inhibited GSK-3 (SB 21673) significantly affected ketamine's actions. To our knowledge, this was the first evidence that ketamine could produce robust changes in clock gene expression. 123 Although these findings offer preliminary evidence to suggest that ketamine alters clock gene expression, it is premature to generalize from data in neuronal cell culture that these actions are relevant to the rapid antidepressant effects in man. As we were not investigating abnormal rhythms, we could not address whether ketamine normalizes dysregulated rhythms. Future work is needed to study the effects of ketamine on clock genes in brain regions relevant to mood disorders in animal models of depression.
Glycogen synthase kinase 3β. GSK-3β is a potent inhibitor of mTORC1 (rapamycin complex 1). Rodent studies demonstrate that inhibition of GSK-3β may have a role in the antidepressant actions of low-dose ketamine. 97, 124, 125 The selective GSK-3β inhibitor, SB 21673, was shown to potentiate ketamine's antidepressant actions in mice 125 and as mentioned above, in our study, 123 the actions of ketamine were specific to SB 21673. Moreover, in GSK-3 knockin mice, ketamine's antidepressant effects in a learned helplessness model of depression were blocked. 97 Mammalian target of rapamycin. Low-dose ketamine robustly activates mTOR, an effect that is thought to help sustain ketaminerelated antidepressant effects beyond the bioavailability of ketamine-primarily due to its actions on AMPA, brain-derived neurotrophic factor and GSK-3β. 8, 121, 122 AMPA. AMPA receptors mediate fast excitatory neurotransmission activation and increase synaptic strength. Upregulation of AMPA following ketamine administration is hypothesized to increase sensitivity to glutamate and stabilize synaptic plasticity. 122 In SCN, AMPA receptors have a critical role in modulating phase-shifts to photic stimuli. Considerations and limitations A limitation to the understanding of SDT and low-dose ketamine's actions involving GSK-3, AMPA, NMDA and mTOR is that there is not enough evidence to identify a specific circadian clock mechanism or a specific circadian defect in MDD. Future research is needed to establish, which, if any of these effects have a critical role in the efficacy of rapid antidepressant responses or if their actions relate to resetting abnormal clock gene rhythms in MDD. Many of the results in circadian research are correlative in nature. Future research should emphasize the importance of direct measurements of circadian function.
DISCUSSION
Abnormal circadian rhythms (sleep, temperature, hormonal secretion and mood) have been consistently reported in a subset of MDD patients. The incidence of depression increases when circadian genes are dysregulated. 1, 2 The severity of depression correlates with the level of desychronization in circadian rhythms. 3 As patients improve, abnormal rhythms circadian rhythms often normalize. 4 It is hypothesized that rapid antidepressant actions involve the modulation of clock genes that control these circadian rhythms. 4 Marked dysregulation in clock gene expression is reported in brain in MDD. 58 SDT and low-dose ketamine rapidly reverses a core pathophysiological deficit in depressive symptomatology in a subset of MDD patients. Preliminary data in MDD and findings in animals show that SD alters circadian clock genes. Low-dose ketamine alters clock genes as reported in neuronal cell culture. 123 It is, however, difficult to extrapolate from neuronal cell culture studies to in vivo rodent or human studies to MDD as to the precise modulation of clock genes. Therefore, at this stage in the research, we could not analyze what is similar and dissimilar in the effects of SD and ketamine on circadian clock genes in MDD patients.
Relatively, little is known about the actions of standard antidepressants on clock gene expression. One study showed an effect of escitalopram on circadian genes in MDD, 126 while a rodent study 127 presented data that SSRIs can modulate circadian rhythms. If clock gene modulation that can occur rapidly is relevant to the efficacy of antidepressant strategies, it is unclear why currently used antidepressant medications require 2-6 weeks to work, while ketamine and SD are effective within 24 h.
Further clock gene research is needed to study effects of other fast-acting antidepressants such as scopolamine, which has clinical efficacy in MDD within a week. 128 In rodents, scopolamine has been shown to activate the mTOR pathway and block muscarinic acetylcholine receptors. Further investigation could determine whether ketamine, SD and scopolamine share downstream targets. 129 In addition, adjustments of human circadian rhythms following jet-lag can take a number of days, which contrasts with the rapid clinical response to ketamine and SD. However, the rapid normalization of abnormal mood in a depressed subject following SD or ketamine may represent an entirely different paradigm than jet-lag in a normal subject. Furthermore, it is reported that a subgroup of vulnerable individuals become severely depressed immediately following abrupt changes in time zones. These episodes are frequently associated with disturbances in sleep. 130, 131 Attempts to treat time-zone precipitated depressive episodes with ketamine or SD have not been documented and therefore it is unclear how rapidly these patients would respond to these interventions.
Future studies Animal studies of ketamine and SD. A limited number of studies in animal models of depression leave a gap in our understanding of the mechanisms of action of rapid antidepressants. Further Figure 1 . Low-dose ketamine and sleep deprivation therapy modulate clock gene machinery, which may represent an important mode of action leading to rapid treatment of depression. Evidence is reviewed that they share additional mechanisms of action involving N-methyl-D-aspartate (NMDA), mammalian target of rapamycin (mTOR), glycogen synthase kinase 3β (GSK-3β) and α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) all of which are modulated by clock genes.
research is required in rodents to determine the effect of ketamine on clock genes in critical brain areas relevant to depression in wild-type mice, but most important, in animal models of depression. In addition, it may be helpful to establish that animals with depressive-like behavior have abnormal circadian rhythms (temperature, activity and hormonal secretion) associated with altered clock genes.
Clinical studies Identify MDD patients with abnormal circadian rhythms (sleep, temperature, hormonal secretion and mood). Study peripheral clock genes to identify whether they are altered in this MDD subgroup. Test the effects of SD and ketamine to determine whether they 'normalize' abnormal clock gene rhythms in periphery. Also, assess circadian rhythms and peripheral clock genes in MDD responders and non-responders to SDT and/or ketamine.
We hope that this review will stimulate scientists to further explore the mechanisms of action of SDT and ketamine and provide insight into mechanisms for sustained rapid responses.
Further investigations could also contribute important data relevant to the hypothesis that SD and ketamine may act by resetting the disrupted clock gene machinery documented in human brain of MDD patients.
Recent research is providing detailed clues to mechanisms involved in phase shifting and resetting of cellular rhythms. As reviewed by Chen et al., 132 the identification of small molecules that modulate and rapidly reset cellular rhythms has motivated the evaluation of synthetic small molecules. These compounds allow more precise control of the circadian machinery and offer the advantage of allosterically altering clock gene proteins. High-throughput screening of 200 000 synthetic small molecules identified a number of molecules with a robust effect on clock gene machinery. These provide clues for lead compounds to target chronotherapeutic treatments of mood disorders and possibly reset abnormal clock gene machinery to normalize circadian rhythms and rapidly treat depression.
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